Hypersensitivity: Introduction, Causes, Mechanism, and Types
Hypersensitivity reactions represent exaggerated or inappropriate immune responses that cause tissue injury, damage, and disease in the host. While the immune system’s primary role is to protect the body against foreign invaders, in hypersensitivity, this defense mechanism overreacts to otherwise harmless environmental antigens (allergens) or, in the case of autoimmune diseases, inappropriately targets the body’s own tissues (autoantigens). These abnormal reactions range in severity from mild discomfort, such as a localized skin rash, to life-threatening conditions like anaphylactic shock, underscoring their critical medical importance. A key characteristic of all hypersensitivity reactions is that they only occur in individuals who have been previously “sensitized” to the specific antigen. The initial, sensitizing exposure produces no symptoms but primes the immune system—generating antibodies or activated specific T-cells—that will then trigger the harmful, symptomatic reaction upon subsequent re-exposure to the same antigen.
The Gell and Coombs Classification System
Hypersensitivity reactions are categorized into four main types—I, II, III, and IV—based on the primary immunological mechanism, the type of effector molecule (antibody or T-cell), and the time taken for the reaction to manifest after re-exposure to the antigen. The first three types (I, II, and III) are mediated by antibodies (IgE, IgG, or IgM), while Type IV is mediated by T-lymphocytes (T-cells) and is thus distinct from the others. Types I, II, and III are often classified as “immediate” (occurring within minutes to hours), whereas Type IV is known as “delayed-type hypersensitivity” (DTH), as it typically takes 24 to 72 hours to develop. It is also possible for a single disease state to involve multiple types of hypersensitivity reactions simultaneously or to have the central reaction type change over the course of the disease.
Type I Hypersensitivity: Immediate and IgE-Mediated
Type I hypersensitivity, commonly known as an allergy, is the most rapidly occurring and widely recognized form, typically manifesting within minutes of allergen exposure. It is canonically mediated by Immunoglobulin E (IgE) antibodies. The *mechanism* requires a two-step process: sensitization and effect. During the initial *sensitization* phase, exposure to an allergen (such as pollen, animal dander, food, or insect venom) triggers the production of allergen-specific IgE antibodies. These IgE molecules have a high affinity for receptors (FcεRI) found on the surface of mast cells and basophils, where they remain bound, effectively “arming” the cell. The *effect* phase begins upon re-exposure. The allergen binds and cross-links two adjacent IgE molecules on the surface of the mast cell. This cross-linking activates the cell, triggering a rapid release, or *degranulation*, of preformed inflammatory mediators stored in the cell’s granules. The primary mediators released are histamine, serotonin, and bradykinin.
These *chemical mediators* are responsible for the characteristic signs and symptoms. Histamine stimulates mucus and tear formation, causing the runny nose and watery eyes of allergic rhinitis (hay fever). Vasodilation can cause hives (urticaria), headaches, and angioedema (swelling). Bronchiole constriction leads to wheezing and difficulty breathing (dyspnea), a hallmark of allergic asthma. Reactions can be *localized*, such as mild allergic rhinitis or hives, or *systemic*, which is referred to as anaphylaxis or anaphylactic shock. Systemic anaphylaxis is a severe, life-threatening reaction characterized by a dangerous drop in blood pressure (hypotension) and extensive airway obstruction due to swelling of the tongue and trachea, which can lead to death within minutes of onset. Furthermore, late-phase reactions may develop 4–12 hours after the early phase, mediated by the subsequent recruitment of eosinophils, neutrophils, and lymphocytes, causing prolonged inflammation.
Type II Hypersensitivity: Cytotoxic and Antibody-Mediated
Type II hypersensitivity reactions, also called cytotoxic hypersensitivity, are mediated by IgG and IgM antibodies that are directed against specific antigens located on the surface of target cells or in the extracellular matrix. The binding of these antibodies is destructive to the cell. The *mechanism of cell damage* primarily involves activation of the complement system and opsonization leading to phagocytosis. When the antibody binds to the cell’s surface antigen, it marks the cell for destruction. Complement activation can directly cause cell lysis via the Membrane Attack Complex (MAC), while opsonization marks the cell to be engulfed and destroyed by phagocytes like macrophages. Alternatively, in a subset of Type II reactions, the antibody binding does not destroy the cell but *alters its normal physiological function* through receptor signaling. Examples include the destruction of red blood cells in incompatible blood transfusions (hemolytic reaction), the destruction of fetal red blood cells in hemolytic disease of the newborn, and several autoimmune diseases such as Graves’ disease (where antibodies enhance signaling) and Myasthenia Gravis (where antibodies inhibit signaling).
Type III Hypersensitivity: Immune Complex-Mediated
Type III hypersensitivity, or immune complex-mediated reaction, involves the interaction of IgG, IgM, and occasionally IgA antibodies with soluble antigens floating freely in the blood. This interaction forms circulating *immune complexes* (antigen-antibody complexes). If these complexes are not efficiently cleared by phagocytes, they can become deposited in the walls of small blood vessels or filter membranes, such as those in the kidney glomeruli, joint spaces, and skin. The deposition of these complexes is the central *mechanism of tissue injury*. Once deposited, the immune complexes activate the complement cascade. This activation produces pro-inflammatory molecules (C3a and C5a, known as anaphylatoxins) that increase vascular permeability and serve as powerful chemotactic factors to recruit inflammatory cells, particularly neutrophils and macrophages, to the site of deposition. The subsequent activation of these recruited cells releases toxic mediators and enzymes, leading to localized inflammation, vasculitis, and tissue damage. Clinical examples include serum sickness, the localized Arthus reaction, and the systemic damage seen in autoimmune diseases like Systemic Lupus Erythematosus (SLE) and certain forms of drug-induced allergies.
Type IV Hypersensitivity: Delayed and T-Cell Mediated
Type IV hypersensitivity is the only type that is not mediated by antibodies; it is *cell-mediated* by T-lymphocytes (T-cells). It is referred to as Delayed-Type Hypersensitivity (DTH) because it typically requires 48 to 72 hours for the reaction to fully develop. The *mechanism* involves previously sensitized T-cells, which are primarily T-helper (Th) cells and cytotoxic T-lymphocytes (CTLs). Upon re-exposure, antigen-presenting cells (APCs) activate the sensitized T-cells. T-helper cells (e.g., Th1) release inflammatory cytokines like interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which activate and recruit macrophages, leading to chronic inflammation and granuloma formation in persistent responses (Type IVa). Cytotoxic T-cells (CD8+) are activated to recognize and directly destroy target cells through the release of perforin and granzyme B (Type IVc). The most common clinical example is *allergic contact dermatitis*, such as the rash from poison ivy, as well as the tuberculin skin test and acute graft rejection. The T-cell-mediated nature makes this type responsible for many chronic inflammatory conditions and long-term immunological tissue damage.
Causes and Factors Driving Hypersensitivity Reactions
The *causes* of hypersensitivity reactions stem from the immune system’s overreaction to various antigens. These antigens can be *extrinsic* (from outside the body), such as: common allergens (pollen, dust mites, animal dander); food substances (peanuts, shellfish); chemicals (nickel); insect venoms; and certain therapeutic drugs. The antigens can also be *intrinsic* (from the body’s own tissues), leading to autoimmune diseases. The susceptibility to develop these reactions is strongly influenced by various *risk factors*. A significant factor is *genetic predisposition*, particularly for Type I reactions (atopy). *Environmental triggers* like air pollution, climate, and socioeconomic status also modulate risk. Crucially, the *Hygiene Hypothesis* proposes that reduced exposure to a diverse range of antigens from microbes and parasites in early life, common in industrialized societies, prevents the immune system from maturing correctly. This lack of stimulation is hypothesized to leave the immune system prone to developing inappropriate, overreactive Th2-type responses, thereby increasing the prevalence of IgE-mediated allergies.